Home » Pipeline
Pipeline
July 19, 2021
| Company | Drug/Device | Medical Condition | Status |
|---|---|---|---|
| Artax Biopharma | AX-158 | T-cell-mediated diseases | phase 1 trial authorized by the UK’s Medicines and Healthcare Products Regulatory Agency |
| iSTAR Medical | MINIject | primary open-angle glaucoma | Investigational Device Exemption (IDE) granted by the FDA |
| Advaxis | ADXS-504 | early prostate cancer | phase 1 trial initiated |
| ENA Respiratory | INNA-051 nasal spray | activation of innate immunity to virus entering through the nose | phase 1 trial initiated |
| Synlogic Therapeutics | SYNB-1934 | phenylketonuria | phase 1 trial initiated |
| Ryvu Therapeutics | RVU120 | acute myeloid leukemia and myelodysplastic syndrome | partial clinical hold on phase 1/b trial removed by the FDA |
| Akeso Biopharma | AK117 in combination with azacitidine | acute myeloid leukemia | phase 1b/2 trial authorized by the National Medical Products Administration of China |
| Enveric Biosciences | EV101 | recurrent or progressive glioblastoma | phase 1/2 trial authorized by the Israeli Ministry of Health |
| Micron Biomedical | microneedle-based measles-rubella vaccine | measles and rubella | phase 1/2 trial initiated in children and adults in Gambia |
| Sigilon | SIG-001 | severe or moderately severe hemophilia A | phase 1/2 trial placed on clinical hold by the FDA |
| ImmunityBio | T-Cell COVID-19 vaccine | boost vaccine in people already vaccinated with a spike-only antibody-based vaccine | phase 1/2/3 trial authorized by the South Africa Health Products Regulatory Authority |
| BriaCell Therapeutics | BRIA-IMT in combination with Incyte’s retifanlimab and epacadostat | advanced breast cancer | phase 1/2a trial initiated |
| CytoDyn | leronlimab | metastatic triple-negative breast cancer | advanced from phase 1b to phase 2 trial |
| Kintor Pharmaceutical | pyrilutamide | androgenetic alopecia | phase 2 trial authorized by the FDA |
| Vir Biotechnology | VIR-2218 with VIR-3434 | chronic hepatitis B virus | phase 2 trial initiated |
| Oryzon | vafidemstat | schizophrenia | phase 2b trial authorized by the Spanish Drug Agency |
| AiCuris | pritelivir | acyclovir-resistant mucocutaneous herpes simplex virus (HSV) infection | phase 3 trial initiated |
| Ortho Clinical Diagnostics | VITROS anti-SARS-CoV-2 IgG quantitative test | COVID-19 diagnosis | Emergency Use Authorization granted by the FDA |
| Astellas | Padcev (enfortumab vedotin-ejfv) | locally advanced or metastatic urothelial cancer | approved by the FDA for expanded indication |
| Bayer | Kerendia (finerenone) | patients with chronic kidney disease associated with type 2 diabetes | approved by the FDA |
| Janssen Biotech | Darzalex Faspro (daratumumab and hyaluronidase-fihj) in combination with pomalidomide and dexamethasone | previously treated multiple myeloma | approved by the FDA for expanded indication |
| Stryker | InSpace balloon implant | arthroscopic treatment of massive irreparable rotator cuff tears | approved by the FDA |
| Cue Health | Cue COVID-19 test | COVID-19 diagnosis | approved by the Central Drugs Standard Control Organization of India |
Upcoming Events
-
28Sep
-
18Oct
